Imprimis Hit With Warning Letter Amidst Lawsuit

Drug Industry Daily
A A
The FDA issued Imprimis Pharmaceuticals a warning letter after finding the firm made misleading claims about its eye care products on its website and social media, saying the violations created a public health concern.

To View This Article:

Login

Subscribe To Drug Industry Daily